SteelPeak Wealth LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,532 shares of the company’s stock, valued at approximately $161,000.
Other hedge funds have also recently made changes to their positions in the company. Mubadala Investment Co PJSC purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth about $128,041,000. Gladstone Institutional Advisory LLC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $133,000. Capstone Investment Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth approximately $161,000. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $34,825,000. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Recursion Pharmaceuticals by 161.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after purchasing an additional 5,680,656 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total value of $95,250.00. Following the transaction, the chief financial officer now directly owns 1,340,968 shares of the company’s stock, valued at approximately $8,515,146.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00. Following the completion of the sale, the chief financial officer now owns 1,340,968 shares of the company’s stock, valued at approximately $8,515,146.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total transaction of $421,000.00. Following the completion of the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $6,388,573.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 258,682 shares of company stock valued at $2,040,718. Insiders own 15.75% of the company’s stock.
Recursion Pharmaceuticals Trading Up 6.5 %
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 86.35% and a negative net margin of 755.37%. The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the business earned ($0.38) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% compared to the same quarter last year. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have recently commented on RXRX shares. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, August 9th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th.
Get Our Latest Analysis on RXRX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
- Five stocks we like better than Recursion Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is the FTSE 100 index?
- Jeff Brown’s Exegesis AI Stock Picks
- The 3 Best Fintech Stocks to Buy Now
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.